Mountain Valley MD Holdings Inc.

Mountain Valley MD Holdings Inc., operating through its subsidiary Mountain Valley MD Inc., functions as a health and wellness enterprise. The company focuses on deploying and licensing its proprietary innovations to external entities within the pharmaceutical, vaccine, and nutritional supplement sectors. Its portfolio encompasses Quicksome, an advanced technology for oral drug formulation and delivery; Quicksol, designed for enhancing solubility; and a dose-sparing adjuvant. Additionally, the firm is actively developing IM032, a compound currently being evaluated in male beagle dogs to assess intramuscular versus subcutaneous administration methods. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.